Overview
Exavir Therapeutics is a venture capital-backed biotechnology company founded in 2020 by Alborz Yazdi, Howard Gendelman, and Benson Edagwa. Headquartered in San Francisco, California, with operations linked to Omaha, Nebraska, Exavir focuses on developing ultra-long-acting nano-medicines for HIV, other viral infections, and central nervous system (CNS) disorders.
Mission and Technology
Exavir Therapeutics aims to enhance patient adherence and outcomes for chronic disorders through its innovative prodrug nanomedicine technology. This technology extends the half-life of small molecule drugs by over 100 times. By formulating ultra-long-acting injectables, Exavir endeavors to significantly improve the convenience, safety, and effectiveness of treatments for millions of HIV patients globally and those at risk of HIV. Their pipeline includes ultra-long-acting integrase inhibitors, positioning Exavir at the forefront of antiviral therapeutic innovation.
Recent Developments
Exavir has secured a $3 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance its ultra-long-acting integrase inhibitor, XVIR-110. In May 2022, the company completed a $4 million seed financing round led by AlleyCorp, with participation from Gilead Sciences, highlighting strong strategic partnerships and financial support. Additionally, Exavir has fortified its intellectual property through a litigation settlement and license agreement with ViiV Healthcare, enhancing its commercial operations.
Leadership
- Brian Kearney, PharmD, Chief Scientific Officer, brings experience from Gilead Sciences and Pardes, contributing to the approval of over 15 antiviral drugs.
- Alborz Yazdi, Co-Founder and President, uses his investment management expertise to lead Exavir’s strategic mission.
- Benson Edagwa, PhD, Co-Founder and Scientific Advisor, is an Associate Professor at the University of Nebraska Medical Center, specializing in macrophage depots for long-acting injectables.
Exavir's Advisory Board consists of notable industry figures such as Edward V. Nunes, MD, and Robert C. Gallo, MD, who provide scientific and strategic guidance.
Strategy and Outlook
Operating at the cutting edge of antiviral drug development, Exavir Therapeutics leverages its proprietary technology to transform antiretroviral treatment paradigms. The company remains poised to capitalize on therapeutic innovations, offering solutions that improve patient outcomes in the management of chronic viral diseases.
Exavir Therapeutics Competitor Profiling
Overview
Exavir Therapeutics specializes in developing ultra-long-acting medicines for chronic viral infections and CNS disorders. The company employs 10-19 individuals and generates an estimated revenue between $1M and $5M, reflecting its innovative approach to addressing unmet medical needs in the biotechnology sector.
Notable Competitors
1. Verismo Therapeutics
- Specialization: Innovates in CAR T-cell therapy, advancing KIR-CAR for solid tumors with a multi-chain immunoreceptor design to enhance antitumor activity.
- Key Developments: SynKIR™ platform provides improved CAR T-cell therapies, reducing T-cell exhaustion.
- Leadership: Founded by Kymriah™ inventors, leading cellular immunotherapy advancements.
2. Carisma Therapeutics
- Specialization: Introduces CAR-Macrophages engaging both innate and adaptive immune systems against solid tumors.
- Clinical Projects: Active in CAR monocyte trials targeting HER2-positive cancers.
- Financial Strength: Secured $30M from a Series C round to expand clinical development.
3. Context Therapeutics
- Focus: Develops TCE bispecific antibody therapies for solid tumors, leading projects like CTIM-76.
- Growth: Raised $100M in a post-IPO equity round, ensuring robust support for ongoing projects.
Market Position
Exavir Therapeutics navigates a competitive landscape with companies like Verismo, Carisma, and Context, each excelling in innovative immune-targeting therapies. To maintain and enhance its market presence, Exavir must continuously innovate and seek collaborations to compete with financially stronger entities and expand its reach in the biotechnology sector. By bolstering innovation and exploring strategic partnerships, Exavir can effectively deliver its novel treatments to broader markets.
